- Home
- LPLA vs TNGX Comparison
LPLA vs TNGX Comparison
Compare LPLA & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPLA
- TNGX
- Stock Information
- Founded
- LPLA 1989
- TNGX 2014
- Country
- LPLA United States
- TNGX United States
- Employees
- LPLA N/A
- TNGX N/A
- Industry
- LPLA Investment Bankers/Brokers/Service
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- LPLA Finance
- TNGX Health Care
- Exchange
- LPLA Nasdaq
- TNGX Nasdaq
- Market Cap
- LPLA 15.8B
- TNGX 735.0M
- IPO Year
- LPLA 2010
- TNGX N/A
- Fundamental
- Price
- LPLA $256.08
- TNGX $6.64
- Analyst Decision
- LPLA Buy
- TNGX Strong Buy
- Analyst Count
- LPLA 15
- TNGX 8
- Target Price
- LPLA $276.86
- TNGX $15.14
- AVG Volume (30 Days)
- LPLA 858.9K
- TNGX 885.7K
- Earning Date
- LPLA 10-30-2024
- TNGX 11-06-2024
- Dividend Yield
- LPLA 0.47%
- TNGX N/A
- EPS Growth
- LPLA N/A
- TNGX N/A
- EPS
- LPLA 12.80
- TNGX N/A
- Revenue
- LPLA $10,930,574,000.00
- TNGX $42,509,000.00
- Revenue This Year
- LPLA $20.61
- TNGX $18.15
- Revenue Next Year
- LPLA $16.64
- TNGX N/A
- P/E Ratio
- LPLA $20.01
- TNGX N/A
- Revenue Growth
- LPLA 16.49
- TNGX 26.16
- 52 Week Low
- LPLA $187.19
- TNGX $6.33
- 52 Week High
- LPLA $289.88
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- LPLA 68.14
- TNGX 37.15
- Support Level
- LPLA $254.31
- TNGX $6.83
- Resistance Level
- LPLA $263.45
- TNGX $7.47
- Average True Range (ATR)
- LPLA 5.52
- TNGX 0.37
- MACD
- LPLA 1.09
- TNGX 0.11
- Stochastic Oscillator
- LPLA 78.48
- TNGX 27.31
About LPLA LPL Financial Holdings Inc.
LPL Financial Holdings is an independent broker/dealer that provides a platform of proprietary technology, brokerage, and investment advisory services to financial advisors and institutions. As of the end of 2023, the company had over 20,000 advisors on its platform managing over $1.3 trillion of client assets.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.